This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Centene (CNC) Loses 5.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Centene (CNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Industry Outlook Highlights Cigna, Humana, Centene and Molina Healthcare
by Zacks Equity Research
CNC, MOH, CI, and HUM are set to benefit from Medicare demand, steady premiums, and tech-driven growth in the HMO space.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 HMO Stocks Set to Thrive From Steady Premium Flows, M&A Strategy
by Debasmita Chatterjee
Rising premiums, ongoing technological innovation and the growing demand for Medicare plans are anticipated to propel the performance of the Zacks Medical-HMO industry players. CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
by Sanghamitra Saha
Top-ranked stocks Centene (CNC), Astera Labs Inc. (ALAB), Five9 (FIVN), Uber Technologies (UBER) and Voya Financial (VOYA) are likely to beat on the bottom line in their upcoming releases.
Should Invesco S&P 500 Pure Value ETF (RPV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RPV
Bet on These 4 Stocks With Exciting Interest Coverage Ratio
by Sumit Singh
URBN, STRL, MOH and CNC show strong interest coverage ratios, signaling solid debt management and earnings strength.
Should Value Investors Buy Centene (CNC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 Value Stocks to Shield Your Portfolio Amid Geopolitical Turmoil
by Sumit Singh
As geopolitical risks jolt markets, STNE, CNC, CVS and PFE shine with low cash flow valuations and solid earnings outlooks.
Centene (CNC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Centene (CNC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Centene (CNC) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Centene (CNC) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer
by Zacks Equity Research
StoneCo, Centene, CVS, and Pfizer stand out as top value picks with strong cash flow amid market uncertainty.
Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook
by Sumit Singh
STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.
Are Investors Undervaluing Centene (CNC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.
Top Stock Reports for Coca-Cola, Abbott & AT&T
by Mark Vickery
Coca-Cola, Abbott, and AT&T beat peers YTD with strong earnings, innovation, and strategic moves, but face headwinds from FX, costs, and competition.
Zacks Investment Ideas feature highlights: Netflix, Eaton and Centene
by Zacks Equity Research
Netflix, Eaton and Centene crushed Q1 earnings, each posting strong results and raising or reaffirming guidance amid broader market uncertainty.
These 3 Companies Crushed Earnings Season
by Derek Lewis
The 2025 Q1 earnings season is slowly grinding down, with these three companies stealing the spotlight during the period.
Brookdale Shares Down 4.9% Despite Q1 Earnings Meeting Estimates
by Zacks Equity Research
BKD continues to witness growth in revenue per available unit (RevPAR). It increases its EBITDA range for 2025.
The Zacks Analyst Blog Highlights UnitedHealth, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, Centene and Molina Healthcare are part of the Zacks top Analyst Blog.
This Is Why UnitedHealth Stock Bounced Back, But Is Better to Avoid
by Tirthankar Chakraborty
Does UnitedHealth's Insiders scooping up shares of UNH justify a buy decision today? Let's explore -
Factors That Make Centene Stock a Lucrative Pick Right Now
by Zacks Equity Research
CNC remains well-poised for growth on improved premiums, a well-performing Commercial Marketplace business, strategic divestitures and sound cash reserves.
Zacks Value Trader Highlights: Centene, Copa and KB Financial
by Zacks Equity Research
Centene, Copa and KB Financial are part of the Zacks Value Trader article.